GKAT yields 0.49% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, GKAT + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GKAT + PFE for your $10,000?
GKAT primarily holds 25 to 40 stocks of any size with strong long-term appreciation potential and limited downside risk. The strategy seeks securities with low valuations combined with growing earnings, cash flow, and/or book value by utilizing five key principles. These include low valuation, discount to fair value, investment flexibility, focus, and a long-term outlook. Investments include common and preferred stocks, rights, warrants, special situations, ADRs, EDRs, and GDRs. At least 40% of the assets are non-US securities. The fund may hold fixed-income securities and ETFs, capped at 30%. It may also fully shift into cash or short-term instruments for liquidity or defensive purposes. Securities are sold when they no longer offer attractive upside or fail to meet valuation and growth criteria. On Aug. 25, 2025, GKAT converted from a mutual fund into an ETF structure, starting with $30.55 million in assets.
Full GKAT Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.